Australian Medical Equipment Stock News

ASX:CSL
ASX:CSLBiotechs

Assessing CSL’s (ASX:CSL) Valuation As Results And Dividend Expectations Confront Recent Growth And Regulatory Headwinds

CSL (ASX:CSL) is back in focus after its share price reacted to fresh anticipation around the upcoming half-year results and interim dividend, with recent guidance changes and regulatory reviews shaping expectations. See our latest analysis for CSL. At A$181.7, CSL’s recent 1 month share price return of 5.36% and 1 day gain of 2.02% suggest short term momentum is building again, although the 1 year total shareholder return of 31.46% decline shows longer term holders are still sitting on...
ASX:SCG
ASX:SCGRetail REITs

Experience-Led Westfield Malls Could Be A Game Changer For Scentre Group (ASX:SCG)

In recent weeks, Scentre Group has drawn fresh attention as investors warm to brick-and-mortar retail amid stabilizing interest rates and resilient retail spending, supported by its Westfield-branded centres across Australia and New Zealand. An interesting angle is how Scentre is leaning into experience-led, community-focused malls with very high occupancy and strong visitor numbers, reinforcing the perceived quality of its A$34.00 billion-plus portfolio. We’ll now examine how this push...
ASX:NST
ASX:NSTMetals and Mining

A Look At Northern Star Resources (ASX:NST) Valuation After Gold Price Drop And Guidance Update

Northern Star Resources (ASX:NST) moved sharply after a significant drop in gold prices hit the broader Australian gold sector, with recent revisions to production and cost guidance adding another layer for investors to assess. See our latest analysis for Northern Star Resources. That sharp move came against a backdrop of choppy trading, with a 14.43% 1 month share price return and 16.86% year to date share price return set against a much stronger 65.36% 1 year total shareholder return. This...
ASX:PNI
ASX:PNICapital Markets

Pinnacle Investment (ASX:PNI) A$17.2b Net Inflows Reinforce Bullish AUM Growth Narrative

Pinnacle Investment Management Group (ASX:PNI) has opened H1 2026 with A$46.1 million in revenue and basic EPS of A$0.30, alongside net income of A$67.3 million, setting a clear earnings benchmark for the half. The company has seen revenue move from A$27.6 million in H1 2025 to A$37.8 million in H2 2025 and then to A$46.1 million in H1 2026. Over the same periods, basic EPS shifted from A$0.37 in H1 2025 to A$0.27 in H2 2025 and A$0.30 in the latest half. Against that backdrop, margins and...
ASX:EVN
ASX:EVNMetals and Mining

A Look At Evolution Mining’s Valuation As Gold Price Slump And RBA Decision Focus Investor Attention

Evolution Mining (ASX:EVN) has come under pressure after a sharp drop in gold prices hit Australian gold stocks, just as investors gear up for the company’s half-year results and a closely watched Reserve Bank of Australia decision. See our latest analysis for Evolution Mining. The sharp pullback after the gold price slump comes against a backdrop of strong recent momentum, with a 30 day share price return of 17.44%, a 90 day share price return of 39.98%, and a very large 3 year total...
ASX:ANZ
ASX:ANZBanks

A Look At ANZ Group Holdings (ASX:ANZ) Valuation As Traders Position For The RBA Meeting

ANZ Group Holdings (ASX:ANZ) has moved into focus as traders position ahead of the Reserve Bank of Australia meeting, where a potential rate hike and guidance could influence funding costs and profit margins. See our latest analysis for ANZ Group Holdings. At a share price of A$37.07, ANZ’s recent moves around the RBA meeting sit against a broader backdrop where short term share price returns have been modest. However, multi year total shareholder returns above 70% suggest momentum has been...
ASX:IPX
ASX:IPXMetals and Mining

A Look At IperionX (ASX:IPX) Valuation After New U.S. Army Prototype Titanium Order

IperionX (ASX:IPX) is back in focus after securing a US$0.3 million prototype purchase order from American Rheinmetall for 700 lightweight titanium components destined for U.S. Army heavy ground combat systems. See our latest analysis for IperionX. The prototype order arrives after a strong period for investors, with IperionX’s 90 day share price return of 16.58% and a 1 year total shareholder return of 58.60%, on top of a very large 3 year total shareholder return. This comes even as the 7...
ASX:AIH
ASX:AIHMachinery

Undiscovered Gems in Australia to Explore February 2026

As the Australian market faces headwinds from a recent Reserve Bank rate hike and global tech sell-offs, small-cap stocks are navigating a challenging landscape. In this environment, identifying promising opportunities involves looking for companies with robust fundamentals and potential resilience to economic shifts.
ASX:ACW
ASX:ACWBiotechs

Actinogen Medical And 2 Other Top-Tier ASX Penny Stocks

The Australian market is facing headwinds as the Reserve Bank's recent rate hike and global tech sell-offs weigh on investor sentiment, with ASX 200 futures indicating a potential downturn. Despite these challenges, opportunities persist in the form of penny stocks, which offer unique investment prospects due to their lower price points and potential for growth. While the term "penny stocks" might seem outdated, these smaller or newer companies can present significant upside when backed by...
ASX:NAB
ASX:NABBanks

Will Eurobond Funding And Mortgage Rate Hike Change National Australia Bank's (ASX:NAB) Interest Income Narrative

National Australia Bank Limited recently completed a €1 billion floating rate senior subordinated Eurobond offering due January 22, 2036, issued at 100% of face value under Regulation S and Rule 144A. This funding move coincides with the Reserve Bank of Australia’s 0.25 percentage point cash rate increase and NAB’s decision to lift standard variable home loan rates from February 13, reshaping its interest income profile and customer cost pressures. We’ll now examine how the Reserve Bank’s...